Literature DB >> 8727505

Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors.

C D Porter1, M K Collins, C S Tailor, M H Parkar, F L Cosset, R A Weiss, Y Takeuchi.   

Abstract

The relative efficiency of transduction of gene therapy target cells was measured for retroviruses bearing the envelopes of amphotropic murine leukemia virus (MLV-A), xenotropic murine leukemia virus (MLV-X), gibbon ape leukemia virus (GALV), feline leukemia virus subgroup B (FeLV-B), and the feline endogenous virus RD114. These viruses use various cell-surface receptors. Activated peripheral blood lymphocytes (PBL) and primary melanoma cultures were infected relatively poorly by MLV-X pseudotypes. RD114 pseudotypes infected PBL relatively well, whereas bone marrow progenitor cells were efficiently infected by all viruses. Helper-free virus bearing the envelopes of MLV-A, RD114, or GALV was similarly tested. All infected melanoma or bone marrow progenitor cells efficiently, whereas MLV-A was relatively inefficient for infection of PBL. The general utility of RD114 pseudotyped virus for gene delivery coupled with its resistance to inactivation by human serum makes this envelope the most suitable choice for in vivo gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8727505     DOI: 10.1089/hum.1996.7.8-913

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor.

Authors:  J L Blond; D Lavillette; V Cheynet; O Bouton; G Oriol; S Chapel-Fernandes; B Mandrand; F Mallet; F L Cosset
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

3.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

4.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.

Authors:  U Blömer; L Naldini; T Kafri; D Trono; I M Verma; F H Gage
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.

Authors:  Kevin M Friedman; Laura E Devillier; Steven A Feldman; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2011 Nov-Dec       Impact factor: 4.456

6.  Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism.

Authors:  L Bruett; J E Clements
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 7.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

8.  Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution.

Authors:  Sandra Blaise; Nathalie de Parseval; Laurence Bénit; Thierry Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

9.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins.

Authors:  Xian-Yang Zhang; Vincent F La Russa; Jakob Reiser
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.